BMJ  2005;330:1262-1264 (28 May), doi:10.1136/bmj.330.7502.1262

Education and debate

No cure, no pay

¹ Department of Social Pharmacy, Danish University of Pharmaceutical Sciences, Universitetsparken 2, DK-2100 Copenhagen Ø, Denmark

Not paying for a drug unless it works sounds great for patients and healthcare funders, but it could also benefit manufacturers.

The first 150 words of the full text of this article appear below.

Introduction

Tensions between the pharmaceutical industry and health authorities over drug marketing have increased in recent decades. The authorities want to get the most possible drug for their money whereas drug companies want to get the most money for their drugs.^{1 2} The current situation is untenable first and foremost for the industry but also for the authorities, and, in the end, the patients. This article proposes how a no cure, no pay strategy could meet the needs of all parties and contribute to a sustainable future for the medical environment as a whole.

Collision course

Marketing tensions are neither new nor odious, but two factors in particular have put the two opposing sides on a collision course. On one side, the authorities have fewer financial resources at their disposal relative to the many drug options available and the increasing need for treatment caused by a swell in the ageing population. Fewer resources naturally . . . [Full text of this article]

No cure, no pay strategy

-->

Examples of no cure, no pay

Optimal product candidates

No cure, no pay, and rational pharmacotherapy

Potential for expansion

Conclusion

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

No need to pay if a drug doesn't work?
BMJ 2005 330: 0. [Full Text]

Winning hearts and minds

Fiona Godlee
BMJ 2005 330: 0. [Extract] [Full Text] [PDF]

Merck offers money back guarantee on finasteride

A Tonks
BMJ 1994 309: 1252-1253. [Extract] [Full Text]

This article has been cited by other articles:

• Hughes, D.A., Tunnage, B., Yeo, S.T. (2005). Drugs for exceptionally rare diseases: do they deserve special status for funding?. QJM 98: 829-836 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

Interesting

Graeme M Mackenzie
bmj.com, 31 May 2005 [Full text]

Let's be serious...

James Penston
bmj.com, 3 Jun 2005 [Full text]

Re: Let's be serious... = facts rather than feelings.

Claus Moldrup
bmj.com, 8 Jun 2005 [Full text]

Drugs: Product or Service?

Markus Lungen, et al.
bmj.com, 10 Jun 2005 [Full text]

Online poll

Find out more >>